Restricted, canonical, stereotyped and convergent immunoglobulin responses

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1676, 2015, Pages

  Dun, Carole J Henry ^a   Wilson, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

B cell; Immunoglobulin; Variable gene

Indexed keywords

ANTIBODY; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; GENE EXPRESSION; GENETIC ANALYSIS; IMMUNE RESPONSE; PATHOLOGY; PROTEIN;

EID: 84937696301     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0238     Document Type: Review

References (68)

1. Wysocki LJ, Gridley T, Huang S, Grandea III AG, Gefter ML. 1987 Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenylarsonate. J. Exp. Med. 166, 1-11. (doi:10.1084/jem.166.1.1)
2. Siekevitz M, Huang SY, Gefter ML. 1983 The genetic basis of antibody production: a single heavy chain variable region gene encodes all molecules bearing the dominant anti-arsonate idiotype in the strain A mouse. Eur. J. Immunol. 13, 123-132. (doi:10. 1002/eji.1830130207)
3. Siekevitz M, Gefter ML, Brodeur P, Riblet R, Marshak-Rothstein A. 1982 The genetic basis of antibody production: the dominant anti-arsonate idiotype response of the strain A mouse. Eur. J. Immunol. 12, 1023-1032. (doi:10.1002/eji. 1830121208)
4. Landolfi NF, Capra JD, Tucker PW. 1986 Germ-line sequence of the DH segment employed in Ars-A antibodies: implications for the generation of junctional diversity. J. Immunol. 137, 362-365.
5. Kuettner MG, Wang AL, Nisonoff A. 1972 Quantitative investigations of idiotypic antibodies. VI. Idiotypic specificity as a potential genetic marker for the variable regions of mouse immunoglobulin polypeptide chains. J. Exp. Med. 135, 579-595. (doi:10.1084/jem.135.3.579)
6. Allen D, Simon T, Sablitzky F, Rajewsky K, Cumano A. 1988 Antibody engineering for the analysis of affinity maturation of an anti-hapten response. EMBO J. 7, 1995-2001.
7. Cumano A, Rajewsky K. 1985 Structure of primary anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies in normal and idiotypically suppressed C57BL/6 mice. Eur. J. Immunol. 15, 512-520. (doi:10.1002/eji.1830150517)
8. Bothwell AL, Paskind M, Reth M, Imanishi-Kari T, Rajewsky K, Baltimore D. 1982 Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region. Cell 24, 625-637. (doi:10.1016/0092-8674 (81)90089-1)
9. Boersch-Supan ME, Agarwal S, White-Scharf ME, Imanishi-Kari T. 1985 Heavy chain variable region. Multiple gene segments encode anti-4-(hydroxy-3- nitro-phenyl)acetyl idiotypic antibodies. J. Exp. Med. 161, 1272-1292. (doi:10.1084/jem.161.6.1272)
10. Gearhart PJ, Sigal NH, Klinman NR. 1977 The monoclonal anti-phosphorylcholine antibody response in several murine strains: genetic implications of a diverse repertoire. J. Exp. Med. 145, 876-891. (doi:10.1084/jem.145.4.876)
11. Claflin JL, Lieberman R, Davie JM. 1974 Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells. J. Exp. Med. 139, 58-73. (doi:10.1084/jem. 139.1.58)
12. Lam KP, Rajewsky K. 1999 B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development. J. Exp. Med. 190, 471-477. (doi:10.1084/jem.190.4.471)
13. White MB, Word CJ, Humphries CG, Blattner FR, Tucker PW. 1990 Immunoglobulin D switching can occur through homologous recombination in human B cells. Mol. Cell. Biol. 10, 3690-3699.
14. Chen K et al. 2009 Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol. 10, 889-898. (doi:10. 1038/ni.1748)
15. Koelsch K et al. 2007 Mature B cells class switched to IgD are autoreactive in healthy individuals. J. Clin. Investig. 117, 1558-1565. (doi:10.1172/ JCI27628)
16. Liu YJ, de Bouteiller O, Arpin C, Briere F, Galibert L, Ho S, Martinez-Valdez H, Banchereau J, Lebecque S. 1996 Normal human IgDþIgM-germinal center B cells can express up to 80 mutations in the variable region of their IgD transcripts. Immunity 4, 603-613. (doi:10.1016/S1074-7613(00)80486-0)
17. Seifert M, Steimle-Grauer SA, Goossens T, Hansmann ML, Brauninger A, Kuppers R. 2009 A model for the development of human IgD-only B cells: genotypic analyses suggest their generation in superantigen driven immune responses. Mol. Immunol. 46, 630-639. (doi:10.1016/j.molimm. 2008.07.032)
18. Zheng NY et al. 2004 Human immunoglobulin selection associated with class switch and possible tolerogenic origins for Cd class-switched B cells. J. Clin. Investig. 113, 1188-1201. (doi:10.1172/ JCI20255)
19. Kaur K, Sullivan M, Wilson PC. 2011 Targeting B cell responses in universal influenza vaccine design. Trends Immunol. 32, 524-531. (doi:10.1016/j.it. 2011.08.007)
20. Gorny MK et al. 2009 Preferential use of the VH5- 51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 46, 917-926. (doi:10.1016/j. molimm.2008.09.005)
21. Gustchina E et al. 2010 Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog. 6, e1001182. (doi:10.1371/journal. ppat.1001182)
22. Luftig MA et al. 2006 Structural basis for HIV-1 neutralization by a gp41 fusion intermediatedirected antibody. Nat. Struct. Mol. Biol. 13, 740-747. (doi:10.1038/nsmb1127)
23. Sabin C et al. 2010 Crystal structure and sizedependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 6, e1001195. (doi:10.1371/journal. ppat.1001195)
24. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009 Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251. (doi:10.1126/science.1171491)
25. Avnir Y et al. 2014 Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 10, e1004103. (doi:10.1371/journal. ppat.1004103)
26. Sui J et al. 2009 Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273. (doi:10.1038/nsmb.1566)
27. Corti D et al. 2010 Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673. (doi:10.1172/JCI41902)
28. Dreyfus C et al. 2012 Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348. (doi:10.1126/science.1222908)
29. Li GM et al. 2012 Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047-9052. (doi:10.1073/pnas. 1118979109)
30. Wrammert J et al. 2011 Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193. (doi:10.1084/ jem.20101352)
31. Thomson CA et al. 2012 Pandemic H1N1 influenza infection and vaccination in humans induces crossprotective antibodies that target the hemagglutinin stem. Front. Immunol. 3, 87. (doi:10.3389/fimmu. 2012.00087)
32. Jackson KJ et al. 2014 Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe 16, 105-114. (doi:10.1016/j.chom.2014.05.013)
33. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE. 2011 Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J. Immunol. 187, 3704-3711. (doi:10.4049/ jimmunol.1101823)
34. Weitkamp JH, Kallewaard NL, Bowen AL, Lafleur BJ, Greenberg HB, Crowe Jr JE. 2005 VH1-46 is the dominant immunoglobulin heavy chain gene segment in rotavirus-specific memory B cells expressing the intestinal homing receptor alpha4beta7. J. Immunol. 174, 3454-3460. (doi:10. 4049/jimmunol.174.6.3454)
35. Di Niro R et al. 2010 Rapid generation of rotavirusspecific human monoclonal antibodies from smallintestinal mucosa. J. Immunol. 185, 5377-5383. (doi:10.4049/jimmunol.1001587)
36. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG. 1998 Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91, 2433-2442.
37. Charles ED, Green RM, Marukian S, Talal AH, Lake- Bakaar GV, Jacobson IM, Rice CM, Dustin LB. 2008 Clonal expansion of immunoglobulin MþCD27þ B cells in HCV-associated mixed cryoglobulinemia. Blood 111, 1344-1356. (doi:10.1182/blood-2007- 07-101717)
38. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Cuoghi A, Torelli G. 2001 Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am. J. Pathol. 159, 253-261. (doi:10.1016/S0002-9440(10)61691-4)
39. Lucas AH, Moulton KD, Tang VR, Reason DC. 2001 Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F. Infect. Immun. 69, 853-864. (doi:10.1128/IAI. 69.2.853-864.2001)
40. Weller S et al. 2004 Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104, 3647-3654. (doi:10.1182/ blood-2004-01-0346)
41. Pauli NT et al. 2014 Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J. Exp. Med. 211, 2331-2339. (doi:10. 1084/jem.20141404)
42. Pascual V, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra JD. 1992 VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J. Immunol. 149, 2337-2344.
43. Potter KN, Li Y, Pascual V, Williams Jr RC, Byres LC, Spellerberg M, Stevenson FK, Capra JD. 1993 Molecular characterization of a cross-reactive idiotope on human immunoglobulins utilizing the VH4-21 gene segment. J. Exp. Med. 178, 1419-1428. (doi:10.1084/jem.178.4.1419)
44. Thompson KM, Sutherland J, Barden G, Melamed MD, Randen I, Natvig JB, Pascual V, Capraj JD, Stevenson FK. 1991 Human monoclonal antibodies against blood group antigens preferentially express a VH4-21 variable region gene-associated epitope. Scand. J. Immunol. 34, 509-518. (doi:10.1111/j. 1365-3083.1991.tb01574.x)
45. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. 2001 Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108, 1061-1070. (doi:10.1172/ JCI200112462)
46. Cho MJ et al. 2014 Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat. Commun. 5, 4167. (doi:10.1038/ ncomms5167)
47. Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR. 2010 Homologous regions of autoantibody heavy chain complementaritydetermining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. J. Clin. Invest. 120, 4111-4117. (doi:10.1172/JCI44425)
48. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G, Boiocchi M. 2002 Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur. J. Immunol. 32, 903-910. (doi:10. 1002/1521-4141(200203)32:3,903::AIDIMMU903.3.0. CO;2-D)
49. Di Niro R et al. 2012 High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat. Med. 18, 441-445. (doi:10.1038/nm.2656)
50. Steinsbo O, Henry Dunand CJ, Huang M, Mesin L, Salgado-Ferrer M, Lundin KE, Jahnsen J, Wilson PC, Sollid LM. 2014 Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells. Nat. Commun. 5, 4041. (doi:10. 1038/ncomms5041)
51. Darzentas N, Stamatopoulos K. 2013 The significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. Hematol. Oncol. Clin. North America 27, 237-250. (doi:10.1016/j.hoc. 2012.12.001)
52. Fais F et al. 1998 Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102, 1515-1525. (doi:10.1172/JCI3009)
53. Efremov DG, Ivanovski M, Siljanovski N, Pozzato G, Cevreska L, Fais F, Chiorazzi N, Batista FD, Burrone OR. 1996 Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 87, 3869-3876.
54. Stamatopoulos K et al. 2005 Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106, 3575-3583. (doi:10.1182/blood-2005- 04-1511)
55. Widhopf II GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. 2004 Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 104, 2499-2504. (doi:10.1182/blood-2004- 03-0818)
56. Hashimoto S et al. 1995 Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgGþ CD5þ chronic lymphocytic leukemia B cells. J. Exp. Med. 181, 1507-1517. (doi:10.1084/jem.181.4.1507)
57. Messmer BT et al. 2004 Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 200, 519-525. (doi:10.1084/jem. 20040544)
58. Ghiotto F et al. 2004 Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J. Clin. Investig. 113, 1008-1016. (doi:10.1172/JCI19399)
59. Tobin G, Soderberg O, Thunberg U, Rosenquist R. 2004 V(H)3-21 gene usage in chronic lymphocytic leukemia-characterization of a new subgroup with distinct molecular features and poor survival. Leuk. Lymphoma 45, 221-228. (doi:10.1080/ 1042819031000147018)
60. Tobin G et al. 2004 Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 104, 2879-2885. (doi:10.1182/blood-2004-01-0132)
61. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E. 2005 Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. 115, 1636-1643. (doi:10.1172/JCI24387)
62. Tobin G et al. 2003 Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 101, 4952-4957. (doi:10.1182/ blood-2002-11-3485)
63. Bikos V et al. 2012 Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 26, 1638-1646. (doi:10. 1038/leu.2012.3)
64. Bikos V et al. 2012 Selection of antigen receptors in splenic marginal-zone lymphoma: further support from the analysis of the immunoglobulin lightchain gene repertoire. Leukemia 26, 2567-2569. (doi:10.1038/leu.2012.207)
65. Miklos JA, Swerdlow SH, Bahler DW. 2000 Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 95, 3878-3884.
66. Darzentas N, Stamatopoulos K. 2013 Stereotyped B cell receptors in B cell leukemias and lymphomas. Methods Mol. Biol. 971, 135-148. (doi:10.1007/ 978-1-62703-269-8_8)
67. Qian J et al. 2014 B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 159, 1524-1537. (doi:10.1016/j.cell. 2014.11.013)
68. Wajanarogana S, Prasomrothanakul T, Udomsangpetch R, Tungpradabkul S. 2006 Construction of a human functional single-chain variable fragment (scFv) antibody recognizing the malaria parasite Plasmodium falciparum. Biotechnol. Appl. Biochem. 44, 55-61.